Therefore, this EPO-overexpressing NIH/3T3 fibroblast cell line may represent a potential material for future studies of cell-based therapies for neurological diseases via the secretion of EPO on a short-term, high-dose, and regional basis. The gene discussed is EPO; the disease is nervous system disorder.